Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation study of DAJH-1050766 tablets in advanced non-small cell lung cancer
CTR20221031Phase 2Active
- Sponsor
- Chengdu Diao Jiuhong Pharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DAJH-1050766 in non-small cell lung cancer (NSCLC), sponsored by Chengdu Diao Jiuhong Pharmaceutical. Started Jul 2022; status: active.
02
Drugs
DAJH-1050766
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221031.